Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2021

01-03-2021 | Targeted Therapy | Clinical

Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy

Authors: Bayan Al-Share, Nour Hammad, Maria Diab

Published in: Cancer and Metastasis Reviews | Issue 1/2021

Login to get access

Abstract

Prognosis from pancreatic ductal adenocarcinoma (PDAC) continues to be poor despite the many efforts channeled to improve its management. Although the mainstay treatment is still traditional chemotherapy, recent advances highlighted a promising potential for targeted therapy in the management of this disease. Those advances emphasize the significance of timely genomic profiling of tumor tissue as well as germline testing of patients to identify potential markers of targeted therapy. While targeted therapy is reserved for a relatively small subset of patients with PDAC, ongoing research is uncovering additional markers, and targeted agents, that will hopefully translate to better outcomes for patients.
Literature
1.
2.
3.
4.
5.
6.
7.
Korc, M., Meltzer, P., & Trent, J. (1986). Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America. https://​doi.​org/​10.​1073/​pnas.​83.​14.​5141.
8.
Shimizu, N., Kondo, I., Gamou, S., Behzadian, M. A., & Shimizu, Y. (1984). Genetic analysis of hyperproduction of epidermal growth factor receptors in human epidermoid carcinoma A431 cells. Somatic Cell and Molecular Genetics. https://​doi.​org/​10.​1007/​BF01534472.
9.
10.
11.
12.
Da Cunha Santos, G., et al. (2010). Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada clinical trials group study PA.3. Cancer. https://​doi.​org/​10.​1002/​cncr.​25393.
13.
14.
Schultheis, B., et al. (2017). Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: A multicenter, randomized phase IIb study. Annals of Oncology. https://​doi.​org/​10.​1093/​annonc/​mdx343.
15.
16.
17.
18.
19.
20.
21.
Burtness, B., Powell, M., Catalano, P., Berlin, J., Liles, D. K., Chapman, A. E., Mitchell, E., & Benson, A. B. (2016). Randomized phase ii trial of irinotecan/docetaxel or irinotecan/docetaxel plus cetuximab for metastatic pancreatic cancer: An eastern cooperative oncology group study. American Journal of Clinical Oncology CANCER CLINICAL TRIALS, 39, 340–345. https://​doi.​org/​10.​1097/​COC.​0000000000000068​.CrossRef
22.
23.
Philip, P. A., et al. (2014). Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO). Cancer. https://​doi.​org/​10.​1002/​cncr.​28744.
24.
25.
26.
27.
28.
29.
T. R. Halfdanarson et al., “A phase II randomized trial of panitumumab, erlotinib, and gemcitabine versus erlotinib and gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance),” Oncologist, 2019, doi: https://​doi.​org/​10.​1634/​theoncologist.​2018-0878.
30.
31.
32.
33.
Veikkola, T., Karkkainen, M., Claesson-Welsh, L., & Alitalo, K. (2000). Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Research.
34.
35.
36.
37.
Watkins, D. J., et al. (2014). The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. European Journal of Cancer. https://​doi.​org/​10.​1016/​j.​ejca.​2014.​02.​003.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
Harder, J., Ihorst, G., Heinemann, V., Hofheinz, R., Moehler, M., Buechler, P., Kloeppel, G., Röcken, C., Bitzer, M., Boeck, S., Endlicher, E., Reinacher-Schick, A., Schmoor, C., & Geissler, M. (2012). Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. British Journal of Cancer, 106, 1033–1038. https://​doi.​org/​10.​1038/​bjc.​2012.​18.CrossRefPubMedPubMedCentral
49.
50.
51.
52.
53.
Schiller, H. B., Szekeres, A., Binder, B. R., Stockinger, H., & Leksa, V. (2009). Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling αVβ3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor. Molecular Biology of the Cell. https://​doi.​org/​10.​1091/​mbc.​E08-06-0569.
54.
55.
56.
57.
58.
59.
Douglas, J. B., Silverman, D. T., Pollak, M. N., Tao, Y., Soliman, A. S., & Stolzenberg-Solomon, R. Z. (2010). Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiology, Biomarkers & Prevention, 19(9), 2298–2306. https://​doi.​org/​10.​1158/​1055-9965.​EPI-10-0400.CrossRef
60.
Abdel-Wahab, R., et al. (2018). Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. Journal of Hematology & Oncology. https://​doi.​org/​10.​1186/​s13045-018-0616-2.
61.
Fuchs, C. S., et al. (2015). A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: The GAMMA trial. Annals of Oncology. https://​doi.​org/​10.​1093/​annonc/​mdv027.​
62.
63.
64.
65.
66.
Cardin, D. B., Thota, R., Goff, L. W., Berlin, J. D., Jones, C. M., Ayers, G. D., Whisenant, J. G., & Chan, E. (2018). A phase II study of ganetespib as second-line or third-line therapy for metastatic pancreatic cancer. American Journal of Clinical Oncology Cancer Clinical Trials, 41, 772–776. https://​doi.​org/​10.​1097/​COC.​0000000000000377​.CrossRef
67.
68.
Hebrok, M., Kim, S. K., St-Jacques, B., McMahon, A. P., & Melton, D. A. (2000). Regulation of pancreas development by hedgehog signaling. Development.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
Cubillo Gracian, A., et al. (2017). YOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus gemcitabine, paclitaxel protein-bound particles for injectable suspension and either 1 or 2 trun. Annals of Oncology. https://​doi.​org/​10.​1093/​annonc/​mdx369.​004.
86.
87.
88.
89.
90.
Xia, J., Duan, Q., Ahmad, A., Bao, B., Banerjee, S., Shi, Y., Ma, J., Geng, J., Chen, Z., Wahidur Rahman, K. M., Miele, L., H Sarkar, F., & Wang, Z. (2012). Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells. Current Drug Targets, 13, 1750–1756. https://​doi.​org/​10.​2174/​1389450128045455​97.CrossRefPubMed
91.
92.
93.
94.
95.
96.
97.
Chikazawa, N., et al. (2010). Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Research.
98.
Kikuchi, A., Yamamoto, H., Sato, A., & Matsumoto, S. (2011). New insights into the mechanism of Wnt signaling pathway activation. In International review of cell and molecular biology.
99.
100.
Makena, M. R., Gatla, H., Verlekar, D., Sukhavasi, S., Pandey, M. K., & Pramanik, K. C. (2019). Wnt/β-catenin signaling: The culprit in pancreatic carcinogenesis and therapeutic resistance. International Journal of Molecular Sciences. https://​doi.​org/​10.​3390/​ijms20174242.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
The Cancer Genome Atlas Research Network, & Raphael, B. J. (2017). Integrated genomic characterization of pancreatic ductal adenocarcinoma The Cancer Genome Atlas Research Network*. Cancer Cell.
119.
120.
121.
122.
123.
124.
125.
126.
127.
Sala, E., Mologni, L., Truffa, S., Gaetano, C., Bollag, G. E., & Gambacorti-Passerini, C. (2008). BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Molecular Cancer Research. https://​doi.​org/​10.​1158/​1541-7786.​MCR-07-2001.
128.
129.
130.
Gowrishankar, K., Snoyman, S., Pupo, G. M., Becker, T. M., Kefford, R. F., & Rizos, H. (2012). Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. The Journal of Investigative Dermatology. https://​doi.​org/​10.​1038/​jid.​2012.​63.
131.
132.
Wrzeszczynski, K. O., et al. (2019). Identification of targetable BRAF Δn486_P490 variant by whole-genome sequencing leading to dabrafenib induced remission of a BRAF-mutant pancreatic adenocarcinoma. Cold Spring Harbor Molecular Case Studies. https://​doi.​org/​10.​1101/​mcs.​a004424.
133.
134.
135.
136.
137.
138.
139.
O’Neil, B. H., et al. (2015). A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Annals of Oncology. https://​doi.​org/​10.​1093/​annonc/​mdv264.
140.
Bedard, P. L., et al. (2015). A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clinical Cancer Research. https://​doi.​org/​10.​1158/​1078-0432.​CCR-14-1814.
141.
142.
143.
Kordes, S., Klümpen, H. J., Weterman, M. J., Schellens, J. H. M., Richel, D. J., & Wilmink, J. W. (2015). Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology. https://​doi.​org/​10.​1007/​s00280-015-2730-y.
144.
145.
Zhou, L., Jiao, X., Peng, X., Yao, X., Liu, L., & Zhang, L. (2020). MicroRNA-628-5p inhibits invasion and migration of human pancreatic ductal adenocarcinoma via suppression of the AKT/NF-kappa B pathway. Journal of Cellular Physiology. https://​doi.​org/​10.​1002/​jcp.​29468.
146.
Elaskalani, O., Domenchini, A., Razak, N. B. A., Dye, D. E., Falasca, M., & Metharom, P. (2020). Antiplatelet drug ticagrelor enhances chemotherapeutic efficacy by targeting the novel P2Y12-AKT pathway in pancreatic cancer cells. Cancers (Basel). https://​doi.​org/​10.​3390/​cancers12010250.​
147.
148.
Zhou, H. Y., Yao, X. M., Chen, X. D., Tang, J. M., Qiao, Z. G., & Wu, X. Y. (2019). Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway. European Review for Medical and Pharmacological Sciences. https://​doi.​org/​10.​26355/​eurrev_​201912_​19666.​
149.
Bodoky, G., Timcheva, C., Spigel, D. R., la Stella, P. J., Ciuleanu, T. E., Pover, G., & Tebbutt, N. C. (2012). A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Investigational New Drugs, 30, 1216–1223. https://​doi.​org/​10.​1007/​s10637-011-9687-4.CrossRefPubMed
150.
151.
Infante, J. R., Somer, B. G., Park, J. O., Li, C. P., Scheulen, M. E., Kasubhai, S. M., Oh, D. Y., Liu, Y., Redhu, S., Steplewski, K., & le, N. (2014). A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. European Journal of Cancer, 50, 2072–2081. https://​doi.​org/​10.​1016/​j.​ejca.​2014.​04.​024.CrossRefPubMed
152.
153.
154.
155.
156.
157.
158.
159.
160.
161.
162.
Sánchez-Elsner, T., Botella, L. M., Velasco, B., Corbí, A., Attisano, L., & Bernabéu, C. (2001). Synergistic cooperation between hypoxia and transforming growth factor-β pathways on human vascular endothelial growth factor gene expression. The Journal of Biological Chemistry. https://​doi.​org/​10.​1074/​jbc.​M104536200.
163.
164.
165.
166.
167.
168.
169.
170.
171.
172.
173.
174.
175.
176.
Clayman, G. L., et al. (1995). In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Research.
177.
Eastham, J. A., et al. (1995). In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Research, 1(1).
178.
179.
180.
181.
182.
183.
184.
Richards, D. A., et al. (2006). Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: Results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Annals of Oncology. https://​doi.​org/​10.​1093/​annonc/​mdl081.
185.
186.
187.
188.
189.
190.
191.
192.
Nakata, B., et al. (2002). Prognostic value of microsatellite instability in resectable pancreatic cancer. Clinical Cancer Research.
193.
Yamamoto, H., et al. (2001). Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Research.
194.
195.
196.
197.
198.
199.
200.
201.
202.
203.
204.
205.
206.
207.
208.
209.
210.
211.
212.
213.
214.
Hiyama, E., et al. (1997). Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Research, 1, 1.
215.
216.
217.
218.
219.
220.
221.
222.
223.
224.
225.
226.
227.
228.
229.
230.
Metadata
Title
Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy
Authors
Bayan Al-Share
Nour Hammad
Maria Diab
Publication date
01-03-2021
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2021
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-020-09948-w

Other articles of this Issue 1/2021

Cancer and Metastasis Reviews 1/2021 Go to the issue

Non-Thematic Review

Targeting the cytoskeleton against metastatic dissemination

Non-Thematic Review

Current methods in translational cancer research

Non-Thematic Review

Secreted frizzled-related protein 2: a key player in noncanonical Wnt signaling and tumor angiogenesis

Non-Thematic Review

Visualizing cancer extravasation: from mechanistic studies to drug development

Clinical

The role of caspase-8 in the tumor microenvironment of ovarian cancer

Non-Thematic Review

An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits